Lipedema is a disorder characterized by massive, bilateral accumulation of fat below the waist and in the legs. Enlargement of the lower extremities is often accompanied by leg pain and accumulation of fluid. Little is known about the functional changes that lead to fat accumulation and pain in women with lipedema. The goals of this project are to conduct a comprehensive characterization of abdominal and femoral fat tissues in lean and obese women with lipedema and to evaluate the potential effect of diet-induced weight loss as a therapy. Once enrolled in the study, the following tests will be conducted on lean women with lipedema: characterization of body composition (fat tissue distribution), insulin sensitivity (response to insulin) and adipose tissue biology. The following tests will be conducted on obese women with lipedema: characterization of body composition (fat tissue distribution), insulin sensitivity (response to insulin), adipose tissue biology, and immune system function/inflammation. As control groups, we will compare body composition and insulin sensitivity to: i) women with obesity without lipedema who are matched on age, body mass index, total body fat mass, and percent body weight as fat; and ii) women who were lean and healthy to serve as a normal comparator for the 2 groups with obesity. Participants in the 2 control groups will enroll in a different study at Washington University (IRB# 201512086) where the same procedures will be performed to assess body composition and insulin sensitivity. A second aim of the study is to determine the effect of diet-induced weight loss on body composition, insulin sensitivity, and adipose tissue biology in women with lipedema. The results from this second aim of the study will provide important insights on the efficacy of diet therapy in managing lipedema.
Once informed consent has been obtained, participants will complete a screening visit that will include a medical history, physical examination, pregnancy test (for women of childbearing potential), blood tests, urine drug test, an oral glucose tolerance test, resting electrocardiogram (ECG), and questionnaires. Baseline testing will be performed over 2 visits requiring 1 inpatient overnight stay and will require approximately 30 hours in total to complete testing. Testing will include magnetic resonance imaging scans to determine thigh fat mass; abdominal (belly) fat mass and liver fat content; DXA scan to assess whole-body and leg fat mass; blood samples; hyperinsulinemic-euglycemic clamp procedure to assess insulin sensitivity; immune system function/inflammation (performed exclusively in people with obesity and lipedema and BMI-matched controls); and adipose tissue (fat) biopsies. Once Baseline Testing is completed, participants will start 5-10% dietitian and/or behaviorist guided weight-loss for about 4 to 6 months. Participant will keep a food diary and have weekly visits (in person or remote) with a study dietitian and/or behaviorist. After weight loss, the testing completed during baseline will be repeated. Study procedures: 1. Medical history \& physical exam 2. Urine drug/pregnancy Test 3. Blood pressure, pulse, height, weight 4. Electrocardiogram (ECG) 5. Blood tests for routine lab analyses 6. Oral glucose tolerance test (OGTT) 7. Screening Questionnaires 8. Dual energy X-ray absorptiometry (DXA) scan to assess whole-body and leg fat mass 9. Magnetic Resonance Imaging (MRI) to determine the amount of fat in the liver, abdomen (belly), and thigh. 10. Metabolism study (hyperinsulinemic-euglycemic clamp procedure) to assess how well insulin works to control blood glucose (sugar) concentrations. 11. Abdominal (belly) and thigh fat biopsies (women with obesity only) 12. Immune function (performed in people with obesity and lipedema only).
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
19
Participants will lose weight by utilizing a low caloric diet and meeting with a study dietitian and/or behaviorist weekly for \~4 months.
Washington University School of Medicine
St Louis, Missouri, United States
Change in thigh subcutaneous adipose tissue volume
Thigh subcutaneous adipose tissue volume assessed by magnetic resonance imaging.
Time frame: Before and after 5-10% weight loss (3-4 months)
Whole-body insulin sensitivity
Whole-body insulin sensitivity determined by using the hyperinsulinemic-euglycemic clamp procedure between women with obesity and women with obesity and lipedema.
Time frame: Baseline testing
Thigh subcutaneous adipose tissue volume
Thigh subcutaneous adipose tissue volume assessed by magnetic resonance imaging in women with obesity and lipedema, women with obesity and lean women.
Time frame: Baseline testing
Change in whole-body insulin sensitivity
Whole-body insulin sensitivity determined by using the hyperinsulinemic-euglycemic clamp procedure.
Time frame: Before and after 5-10% weight loss (3-4 months)
Leg fat mass
Leg fat mass will be assessed by dual-energy x-ray absorptiometry (DXA) in women with obesity and lipedema, women with obesity and lean women.
Time frame: Baseline testing
Change in leg fat mass
Leg fat mass will be assessed by dual-energy x-ray absorptiometry (DXA).
Time frame: Before and after 5-10% weight loss (3-4 months)
Adipose tissue immune cells
Immune cell numbers in upper and lower body subcutaneous adipose tissue stromal vascular fraction content assessed by flow cytometry in women with obesity and lipedema only.
Time frame: Baseline testing
Change in adipose tissue immune cells
Immune cell numbers in upper and lower body subcutaneous adipose tissue stromal vascular fraction content assessed by flow cytometry.
Time frame: Before and after 5-10% weight loss (3-4 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.